Life Sciences Companies To Steer Patents Away From New European Court
This article was originally published in Scrip
Executive Summary
All healthcare and life sciences companies that responded to a survey by the law firm Hogan Lovells will opt their most important patents out of the European Unified Patent Court. The findings signal cautious joined up thinking on how companies will approach the new court, which is scheduled to launch in 2017.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.